Related Experiment Video
Updated: May 2, 2026
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Modifications in relaxin's serum levels during acetate-free biofiltration (AFB): only a new biomarker?
Aims:
We evaluated relaxin's behaviour during a haemodialytic session and the effects of its intradialytic variability on blood pressure.
Methods:
We enrolled 25 patients and evaluated relaxin's levels during a haemodialytic session. We also dosed interdialytic relaxin and enrolled 10 healthy subjects and 16 patients with III stage chronic renal failure as controls.
Results:
Haemodialyzed patients have relaxin's baseline concentrations higher than healthy controls, but lower than chronic patients. During the treatment, relaxin is removed; it increases again throughout the interdialytic phase. Furthermore, relaxin's pre- haemodialytic concentration positively and significantly correlates with systolic, diastolic, and mean BP; such correlations disappear at the end of the treatment.
Conclusion:
Relaxin's removal during the treatment may intervene in the pathogenesis of intradialytic hypertension. Hence, relaxin could be not only a new biomarker but also an active player in the intradialytic variations of blood pressure.
